Arteriovenous Plasma Multiomics in Patients With Disorders of Consciousness

Arteriovenous Plasma Multiomics and Inflammatory Factors in Patients With Disorders of Consciousness

In order to determine the abnormal cerebral metabolism in the pathological state, we compared the blood of internal jugular vein, superior vena cava and radial artery during central venous catheterization. Metabonomics, proteomics and inflammatory factor microarray were used to detect the material differences in arteriovenous blood of patients with disorders of consciousness. At the same time, we concurrently compared it with the peripheral plasma metabolome of two additional patient cohorts: those in-stent restenosis and non-restenosis.

Study Overview

• Status: Completed
• Conditions: Transient Ischemic Attack; Disorders of Consciousness
• Intervention / Treatment: Other: No intervention

Detailed Description

Background:It is unclear what substances the brain needs to ingest for its activity under pathological conditions

Method:The uptake and release of substances by the brain were observed by comparing arterial blood with internal jugular vein blood;The characteristics of brain metabolites were observed by comparing internal jugular vein blood with superior vena cava blood. Compared it with the peripheral plasma metabolome of two additional patient cohorts: those in-stent restenosis and non-restenosis.

Objective:By analyzing different substances, this paper briefly describes the pathological mechanism of patients with disorders of consciousness, and looks for potential prognostic biomarkers.

• Study Type: Observational
• Enrollment (Actual): 100

Contacts and Locations

Study Locations

• China
  • Zhejiang
    • Hanzhou, Zhejiang, China, 310003
      • The First Affiliated Hospital of Zhejiang University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Patients with consciousness disorder caused by various severe brain injuries were recruited at Intensive care unit of The First Affiliated Hospital of Zhejiang University and Intensive care unit of the Second Affiliated Hospital of Zhejiang University

Description

Inclusion Criteria:

1.Patients with consciousness disorder caused by various severe brain injuries

Exclusion Criteria:

1. Patients who have been judged brain dead
2. There are persistent epileptic activity, inhibition or seizure inhibition patterns
3. Recent fever, abnormal liver and kidney function
4. Previous history of neurological or mental illness
5. Have a history of tumor
6. Inflammatory bowel diseases, hyperlipidemia, gastritis

Study Plan

How is the study designed?

Number of groups / cohorts

4

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Minimally conscious state (MCS); Minimally conscious state (MCS): have reproducible signs of awareness and exhibit fluctuations in consciousness	Other: No intervention; No intervention
Vegetative state (VS); Vegetative state (VS): can open their eyes and preserve sleep-wake cycles, but unaware of themselves and their surroundings	Other: No intervention; No intervention
Patients with In-Stent Restenosis; In-Stent Restenosis was defined as greater than 50% within or immediately adjacent (within 5 mm) to the stent implanted that was detected by digital subtraction angiography (DSA).	Other: No intervention; No intervention
Patients with Non-Restenosis; In-Stent Restenosis was defined as less than 50% within or immediately adjacent (within 5 mm) to the stent implanted that was detected by digital subtraction angiography (DSA).	Other: No intervention; No intervention

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Patient clinical outcome	The patients were followed up for 12 months after blood collection to observe the clinical outcome	12 months

Collaborators and Investigators

• Sponsor: First Affiliated Hospital of Zhejiang University

Study record dates

Study Major Dates

• Study Start (Actual): May 1, 2022
• Primary Completion (Actual): March 30, 2024
• Study Completion (Actual): April 30, 2024

Study Registration Dates

• First Submitted: March 14, 2022
• First Submitted That Met QC Criteria: May 6, 2024
• First Posted (Actual): May 7, 2024

Study Record Updates

• Last Update Posted (Actual): May 7, 2024
• Last Update Submitted That Met QC Criteria: May 6, 2024
• Last Verified: March 1, 2022

More Information

Terms related to this study

• Keywords: Plasma metabolism
• Additional Relevant MeSH Terms: Mental Disorders; Cardiovascular Diseases; Vascular Diseases; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neurologic Manifestations; Neurobehavioral Manifestations; Neurocognitive Disorders; Brain Ischemia; Ischemic Attack, Transient; Consciousness Disorders
• Other Study ID Numbers: plasma multiomics

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No